TEM vs RXRX
TEM and RXRX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | TEMTempus AI, Inc. | RXRXRECURSION PHARMACEUTICALS, INC. |
|---|---|---|
| Market cap | $12.34M | $1.73B |
| P/B | 0.03 | — |
| P/S | 0.0x | 23.2x |
| Revenue | $1.43B(TTM) | — |
| Revenue growth (YoY) | 83.4% | 26.9% |
| Net income | -$254.40M(TTM) | — |
| Earnings growth (YoY) | 65.3% | -39.1% |
| EPS, diluted | $-1.44(TTM) | — |
| EBIT margin | -19.9% | -867.9% |
| ROE | -55.1% | -70.5% |
| ROIC | — | -175.2% |
| 1y total return | -19.2% | -32.3% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: TEM frente a RXRX
| Métrica | TEM | RXRX |
|---|---|---|
| Valor final | $17.1K | $3.5K |
| Retorno total | +71.1% | -65.0% |
| CAGR | +26.9% | -37.3% |
| Volatilidad | 97.6% | 82.7% |
| Sharpe | 0.68 | -0.21 |
| Sortino | 1.09 | -0.32 |
| Caída máxima | -59.8% | -73.9% |
Basado en 564 días de negociación comunes, 2024-06-14 → 2026-09-15 · tasa libre de riesgo 4.11% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)